GlassScriptPhysician profile
Ryan W Lahey
NPI 1346602760
$1,834.73
in general payments reported to CMS, 2019-2025
15 companies · $47.01 in 2025
The $47.01 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $393 · 2021: $424 · 2022: $343 · 2023: $265 · 2024: $195 · 2025: $47.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $505.23 | 2019-2025 | Cardiomems, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.73 | 2021-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $228.78 | 2022-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $179.47 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.62 | 2021-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $86.76 | 2022-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $80.11 | 2022-2024 | |
| Pfizer INC. | $27.89 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $27.70 | 2022 | |
| Medtronic, INC. | $27.11 | 2021 | |
| Boston Scientific Corporation | $26.40 | 2025 | Vigilant X4 Crt-D |
| Regeneron Healthcare Solutions, INC. | $25.82 | 2021 | |
| Novo Nordisk INC | $24.96 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.77 | 2024 | Arcalyst |
| Amgen INC. | $13.38 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.